Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.5 - $8.1 $1.55 Million - $2.28 Million
-281,000 Closed
0 $0
Q2 2024

Aug 14, 2024

BUY
$5.91 - $10.23 $1.15 Million - $1.99 Million
194,812 Added 226.03%
281,000 $1.87 Million
Q1 2024

May 13, 2024

BUY
$8.22 - $13.81 $620,840 - $1.04 Million
75,528 Added 708.52%
86,188 $877,000
Q4 2023

Oct 21, 2024

SELL
$2.14 - $11.62 $22,660 - $123,044
-10,589 Reduced 49.83%
10,660 $119,000
Q4 2023

Feb 07, 2024

BUY
$2.14 - $11.62 $22,812 - $123,869
10,660 New
10,660 $119,000
Q2 2023

Oct 21, 2024

SELL
$3.45 - $5.97 $922,705 - $1.6 Million
-267,451 Reduced 92.64%
21,249 $75,000
Q2 2023

Aug 07, 2023

SELL
$3.45 - $5.97 $922,705 - $1.6 Million
-267,451 Reduced 92.64%
21,249 $75,000
Q1 2023

Oct 21, 2024

BUY
$4.19 - $16.83 $32,263 - $129,590
7,700 Added 2.74%
288,700 $1.22 Million
Q1 2023

May 03, 2023

BUY
$4.19 - $16.83 $1.21 Million - $4.86 Million
288,700 New
288,700 $1.22 Million
Q2 2022

Aug 09, 2022

SELL
$3.94 - $11.77 $40,188 - $120,054
-10,200 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$5.9 - $9.45 $207,680 - $332,640
-35,200 Reduced 77.53%
10,200 $62,000
Q4 2021

Feb 10, 2022

BUY
$8.69 - $12.48 $394,526 - $566,592
45,400 New
45,400 $416,000
Q2 2021

Aug 13, 2021

SELL
$9.85 - $16.46 $518,612 - $866,635
-52,651 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$12.71 - $24.31 $202,737 - $387,768
15,951 Added 43.46%
52,651 $744,000
Q4 2020

Feb 12, 2021

SELL
$7.84 - $14.22 $156,016 - $282,978
-19,900 Reduced 35.16%
36,700 $414,000
Q3 2020

Nov 13, 2020

BUY
$9.93 - $33.26 $562,038 - $1.88 Million
56,600 New
56,600 $747,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $395M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.